Citations

Clear

133 citation(s) found for "Fernandes, B C".

Abstract 18767: Race-related Disparities in Ventricular-arterial Coupling in Elderly Individuals: The Atherosclerosis Risk in Communities Study
Fernandes-Silva, Miguel Morita , Claggett, Brian , Solomon, Scott D. , Shah, Amil M. , Hegde, Sheila M. , Gonçalves, Alexandra , Cheng, Susan , Nadruz, Wilson , Lam, Carolyn S.P. , Borlaug, Barry A. , Solomon, Scott David

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.18767 Get It

Introduction: The incidence of heart failure (HF) is higher in black than in white Americans, but the causes are unclear. We proposed that ethnic differences in ventricular-arterial interaction may contribute to this differential HF risk. Methods: We studied measures of arterial elastance (Ea) and left ventricle (LV) end-systolic elastance (Ees) in 5767 community-based elderly participants (76±5 years, 41% male, 22% black) who underwent echocardiography in the Atherosclerosis Risk in Community (ARIC) Study. Results: Black participants were more frequently women (66 vs 57%) and had a higher prevalence of obesity (46 vs 31%), hypertension (94 vs 80%), and diabetes mellitus (47 vs 34%). Adjusting for these baseline differences, the prevalence of LV hypertrophy was similar, but Ea, Ees and Ea/Ees ratio were higher in blacks than whites, particularly in black women (Figure). Ea was positively associated with LV mass index and E/e’ ratio in blacks, but not in whites (p for interaction < 0.001). Conclusion: These community-based data demonstrate that ventricular-arterial stiffening is greater in black than white Americans, coupled with more ventricular remodeling and dysfunction. The heightened afterload dependence in blacks suggests greater potential for risk reduction with anti-hypertensive therapy.
The Global Reading Room: Nuclear Medicine Imaging of a Diabetic Foot Ulcer
Israel, Ora , Nakajo, Masatoyo , Nunes, Rafael Fernandes , Packard, Annie T.

Mayo Clinic

American Journal of Roentgenology | January 5, 2022 | Volume: 219 | Issue: 4 | Pages: 681-682

10.2214/ajr.21.27251 | PMID 34985310 Get It

Increased Risk for Maternal Anxiety during the COVID-19 Outbreak in Brazil among Pregnant Women without Comorbidities
Nomura, Roseli Mieko Yamamoto , Ubinha, Ana Carla Franco , Tavares, Isabela de Paula , Costa, Maria Laura , Opperman, Maria Lucia da Rocha, Brock, M. , Trapani, Alberto , Damásio, Lia Cruz Vaz da Costa , Reis, Nadia Stella Viegas , Borges, Vera Therezinha Medeiros , Araújo, Ana Cristina Pinheiro Fernandes de , Opperman, Maria Lucia , Brock, Marianna Facchinetti , Zaconeta, Alberto , Araujo, Ana Cristina Pinheiro Fernandes de , Ruano, Rodrigo , Nomura, Roseli , Trapani, Alberto , Damasio, Lia , Borges, Vera , Opperman, Maria Lúcia, Ruano, Rodrigo

Mayo Clinic

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics | December 21, 2021 | Volume: 43 | Issue: 12 | Pages: 932-939

10.1055/s-0041-1740234 | PMID 34933387 Get It

Abstract Objective To study maternal anxiety in pregnant women without comorbidities in the context of the COVID-19 outbreak in Brazil and to study maternal knowledge and concerns about the pandemic. Methods This is a secondary analysis from a national multicenter cross-sectional study performed in 10 cities, from June to August, 2020, in Brazil. Interviewed postpartum women, without medical or obstetrical comorbidities, were included in the present subanalysis. A structured questionnaire and the Beck Anxiety Inventory (BAI) were applied. Results Out of the 1,662 women, 763 (45.9%) met the criteria for the current analysis and 16.1% presented with moderate and 11.5% with severe maternal anxiety. Moderate or severe maternal anxiety was associated with high school education (odds ratio [OR]:1.58; 95% confidence interval [CI]:1.04–2.40). The protective factor was cohabiting with a partner (OR: 0.46; 95%CI: 0.29–0.73). There was a positive correlation between the total BAI score and receiving information about care in the pandemic (rpartial 0.15; p < 0.001); concern about vertical transmission of COVID-19 (rpartial 0.10; p = 0.01); receiving information about breastfeeding (rpartial 0.08; p = 0.03); concerns about prenatal care (rpartial 0.10; p = 0.01), and concerns about the baby contracting COVID-19 (rpartial 0.11; p = 0.004). The correlation was negative in the following aspects: self-confidence in protecting from COVID-19 (rpartial 0.08; p = 0.04), having learned (rpartial 0.09; p = 0.01) and self-confidence in breastfeeding (rpartial 0.22; p < 0.001) in the context of the pandemic. Conclusion The anxiety of pregnant women without medical or obstetrical comorbidities was associated to high school educational level and not living with a partner during the COVID-19 pandemic. Self-confidence in protecting against COVID-19 and knowledge about breastfeeding care during the pandemic reduced maternal anxiety.
Mortality from snakebite envenomation: an analysis from the Global Burden of Disease Study 2019
Roberts, Nicholas L S , Johnson, Emily K. , Zeng, Scott , Hamilton, Erin B, Alahdab, Fares , Alipour, Vahid, Andrei, Cătălina Liliana , Arabloo, Jalal , Badiye, Ashish , Bakkannavar, Shankar M , Bhalla, Ashish, Bijani, Ali , Cai, Tianji , Carvalho, Félix , Chu, Dinh‐Toi , Couto, Rosa A S, Desta, Abebaw Alemayehu, Earl, Lucas, Eftekhari, Aziz , Esmaeilzadeh, Firooz , Gebregiorgis, Birhan Gebresillassie , Ghashghaee, Ahmad , Golechha, Mahaveer , Haque, Syed Arefinul , Kapoor, Neeti , Khan, Ejaz Ahmad , Khundkar, Roba , Krishan, Kewal , Kumar, G Anil , Lim, Stephen S , Manafi, Navid , Miller, Ted R. , Mokdad, Ali A, Monteiro, Francis N.P., Moradi, Maryam , Nguyen, Cuong Tat , Nguyen, Huong Lan Thi , Ostroff, Samuel M, Pham, Hai Quang , Rabiee, Navid , Rao, Sowmya R. , Rawaf, David Laith , Reiner, Robert C. , Samy, Abdallah M , Sawhney, Monika, Schwebel, David C. , Senthilkumaran, Subramanian , Shaikh, Masood Ali , Tovani‐Palone, Marcos Roberto , Travillian, Ravensara S., Velazquez, Diana Zuleika , Zhang, Zhi‐Jiang , Naghavi, Mohsen , Dandona, Rakhi , Dandona, Lalit , James, Spencer L , Murray, Christopher, Hay, Simon I , Vos, Theo , Abdoli, Amir , Ancuceanu, Robert , Anvari, Davood , Ausloos, Marcel , Awedew, Atalel Fentahun , Bhardwaj, Nikha , Bhardwaj, Pankaj , Bhaumik, Soumyadeep , Boloor, Archith , Dai, Xiaochen , Do, Hoa , Farzadfar, Farshad , Fernandes, Eduarda , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gaidhane, Abhay Motiramji , Gebremichael, Berhe , Hamidi, Samer , Haque, Syed, Hayat, Khezar , Herţeliu, Claudiu , Ilesanmi, Olayinka Stephen , Islam, M. Mofizul , Jagnoor, Jagnoor , Kanchan, Tanuj , Khatib, Mahalaqua Nazli , Kumar, Nithin , Landires, Iván , Madadin, Mohammed , Maled, Venkatesh , Marczak, Laurie B. , Menezes, Ritesh G. , Meretoja, Tuomo J , Mohammadian-Hafshejani, Abdollah , Nayak, Vinod C , Núñez-Samudio, Virginia , Padubidri, Jagadish Rao , Pinheiro, Marina , Pirestani, Majid , Zahiruddin, Quazi Syed , Radfar, Amir , Rahimi‐Movaghar, Vafa , Rastogi, Prateek , Rawaf, Salman , Sahebkar, Amirhossein , Skryabin, Valentin Yurievich , Skryabina, Anna Aleksandrovna , Soheili, Amin , Stokes, Mark Andrew , Thapar, Rekha , Tran, Bach Xuan , Pigott, David M. , Ong, Sok King , Alahdab, Fares

Mayo Clinic

No container title available | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1021472/v1 Get It

Abstract Venomous snakebite is an important cause of preventable death. The World Health Organization (WHO) set a goal to halve snakebite mortality by 2030. We used verbal autopsy and vital registration data to model the proportion of venomous animal deaths due to snakes by location, age, year, and sex, and applied these proportions to venomous animal contact mortality estimates from the Global Burden of Disease 2019 study. In 2019, 63,400 people (95% uncertainty interval 38,900–78,600) died globally from snakebites, which was equal to an age-standardized mortality rate (ASMR) of 0.8 deaths (0.5–1.0) per 100,000 and represents a 36% (2–49) decrease in ASMR since 1990. India had the greatest number of deaths in 2019, equal to an ASMR of 4.0 per 100,000 (2.3-5.0). We forecast mortality will continue to decline, but not sufficiently to meet the WHO’s goals. Improved data collection should be prioritized to help target interventions, improve burden estimation, and monitor progress.
International Consensus Statement on Nomenclature and Classification of the Congenital Bicuspid Aortic Valve and Its Aortopathy, for Clinical, Surgical, Interventional and Research Purposes
Michelena, Héctor I. , Corte, Alessandro Della , Evangelista, Arturo , Maleszewski, Joseph J. , Edwards, William D. , Roman, Mary J. , Devereux, Richard B. , Fernández, Borja , Asch, Federico M. , Barker, Alex J. , Sierra-Galán, Lilia M. , Delgado, Victoria , Lansac, Emmanuel , Bissell, Malenka M. , Hope, Michael D. , Sitges, Marta , Thourani, Vinod H. , Pibarot, Phillippe, Chandrasekaran, Krishnaswamy , Lancellotti, Patrizio , Forrest, John K. , Webb, John G. , Makkaar, Raj, Leon, Martin B. , Markl, Michael , Ferrari, Victor A. , Roberts, William C. , Svensson, Lars G. , Braverman, Alan C. , Bavaria, Joseph E. , Sundt, Thoralf M. , Khoury, Gébrine El , Paulis, Ruggero De , Fernandes, Susan M , Fedak, Paul W M , Abbara, Suhny , Bissell, Malenka M , Popescu, Bogdan A , Hope, Michael D , Pibarot, Phillippe , Chandrasekaran, Krishnaswamy , Forrest, John K , Markl, Michael , Ferrari, Victor A , White, Charles S , Braverman, Alan C , De Paulis, Ruggero , Michelena, Hector I , Della Corte, Alessandro , Barker, Alex J , Delgado, Victoria , Enriquez-Sarano, Maurice , De Kerchove, Laurent , Girdauskas, Evaldas , Prakash, Siddharth K. , Popescu, Bogdan A. , Borger, Michael A. , Milewicz, Dianna M. , Sanders, Stephen Pruett , Song, Jae‐Kwan , Blanke, Philipp , Siu, Samuel , Enriquez‐Sarano, Maurice , Bax, Jeroen J. , Otto, Catherine M , Schäfers, Hans‐Joachim

Mayo Clinic

Radiology: Cardiothoracic Imaging | July 22, 2021 | Volume: 3 | Issue: 4 | Pages: e200496

10.1148/ryct.2021200496 | PMID 34505060 Get It

Biallelic splicing variants in the nucleolar 60S assembly factor RBM28 cause the ribosomopathy ANE syndrome
Bryant, Carson J. , Lorea, Cláudia Fernandes , Almeida, Hiram Larangeira de , Weinert, Letícia Schwerz , Vedolin, Leonardo , Baserga, Susan J. , Lorea, Cláudia F , de Almeida, Hiram Larangeira , Weinert, Letícia , Vairo, Filippo , Baserga, Susan J , Vairo, Filippo Pinto e

Mayo Clinic

Proceedings of the National Academy of Sciences | May 3, 2021 | Volume: 118 | Issue: 19 | Pages: No page available

10.1073/pnas.2017777118 | PMID 33941690 Get It

Significance RBM28 is a human protein essential for proper assembly of the large ribosomal subunit, crucially enabling synthesis of all cellular proteins. Defects in RBM28 cause rare ribosomopathies: alopecia, neurological defects, and endocrinopathy (ANE) syndrome. We investigated an ANE syndrome patient with a clinical presentation consistent with the definition of ANE syndrome but possessing differing genetic variants and molecular pathology. We find one inherited allele is null, clarifying that ANE syndrome is not caused by RBM28 haploinsufficiency, while the other inherited allele retains enough function to enable survival but preclude proper development. Our results define an underlying pathology of ANE syndrome, further delineating an emerging class of assembly factor ribosomopathies and underscoring the importance of nucleolar processes in human health.
Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries
Russotto, Vincenzo , Laffey, John G. , Tassistro, Elena , Camporota, Luigi , Higgs, A. , Putensen, Christian , Agvald‐Öhman, Christina, Bokums, Kristaps, Brewster, David , Rossi, Emanuela , Fumagalli, Roberto , Pesenti, Antonio, Investigators, INTUBE Study, Ahmed, Hazem , Adhikari, Neill K. J. , Agrawal, Kehari, Agrawal, Nipun , Aguirre-Bermeo, Hernán , Agvald-Öhman, Christina, Ahmad, Meraj, Ajami, Samareh, Akhtar, Shazia N., Alghamdi, Adnan, Alhadi, Abdulmueti , Ali, Syed Muhammad Adnan , Ali, Mohd N., Alias, Anita, Alonso, Julio, Montenegro, Diana Alvarez, Aman, Rubina, Anstey, Matthew , Αrnaoutoglou, Eleni , Baccari, Laura, Baliga, Nishanth, Manjunath, Ramya Ballekatte, Bamane, Shrirang, Bandert, Anna , Bartholdy, Roland, Baturova, Vera , Bellissima, Agrippino , Belsky, Vladislav, Bendre, Prashant, Benini, Annalisa, Besset, Sébastien , Bhattacharyya, Mahuya , Bielański, Piotr, Bigatello, Luca M., Boissier, Florence , Bonney, Iwona, Bowen, David , Boyer, Alexandre, Broman, Lina , Bruel, Cédric , Brunin, Yannick, Bugedo, Guillermo , Calamai, Italo , Campos, Patricia , Canavosio, Federico Giovanni , Cascella, Marco , Catorze, Nuno , Champigneulle, Benoît , Chandwani, Juhi, Chaurasia, Satish, Chawla, Rajesh , Chawla, Aakanksha, Cheetham, Olivia, Chemouni, Frank , Kiok, Lee Chew, Chimunda, Timothy , Chiu, Ching‐Tang , Chiumiento, Fernando, Chudeau, Nicolas , Colica, Sandra, Colin, Gwenhaël , Constantin, Jean‐Michel , Contou, Damien , Costa, Paulo F., Costa, Vasco , Cracchiolo, Andrea, Crone, Petra, Cunha, Rui Pedro, Radivojević, Renata Curić , Dash, Sampat, Pascale, Gennaro De , Torre, Valentina Della, Caprio, Barbara Di, Dimitropoulou, Aikaterini, Edmunds, Christopher , El-Fellah, Nadia, Elhadi, Ahmed , Escudero-Acha, P. , Espinoza, Missael, Esposito, Clelia, Fabretti, Fabrizio, Fein, Daniel , Ferluga, Massimo, Ferré, Alexis , Ferrier, Janet, Flaksa, Marek, Flores, Fernando , Gonzalez, Jesus Flores, Fuentes, Xavier Fonseca , Francis, Roland C. E. , Franco, Daniela G., Franczyk, Pawel, Furman, Mikhail, Gałkin, Piotr, Aguilera, Maria F. García, Garofalo, Eugenio , Gatward, Jonathan, Ghula, Mohamed , Giacomucci, Angelo , Giovannini, Ilaria , Gnanadurai, Kingsly Robert, Godet, Thomas, Fernandez, Gemma Goma , González, María del Carmen Martín, González, Daira, Gopalakrishna, Kadarapura Nanjundaiah , Gottesman, Eric , Gros, Alexandre, Gupta, Manish , Gupta, Kulbhusahn, Hamid, Tarikul , Hamzaoui, Olfa, Hannesdottir, Katrin, Hasan, Shahnaz, Hossain, Mozaffer, Hossein, Sazzad, Hraiech, Sami , Hypes, Cameron, Alkhumsi, Soad Imhmed R., Islam, Motiul, Ismail, Muhamad A., Ivančan, Višnja , Jacquier, Sophie , Jagiasi, Bharat, Jain, Nikhilesh , Jamaluddin, Muhamad Fadhil Hadi, Jeswani, Deepak , Jeswani, Deepti, Jha, Simant , Jones, Benjamin , Jozwiak, Mathieu , Jumić, Aleksandra, Kamp, Oliver , Karametos, Ilias, Karelov, Alexey, Kaufman, David A. , Kaushik, Shuchi, Kesavarapu, Subba R., Khaled, Ala , Khalidah, Hapiz, Khunteta, Sudhir , Kindgen‐Milles, Detlef , Korula, Sara , Kothekar, Amol , Koul, Salman S., Krog, Ditte, Kuellmar, Mira, Kuragayala, Swarna Deepak , Kyparissi, Aikaterini, Labarca, Gonzalo , Lalwani, Jaya, Landaverde, Antonio, Lehr, Andrew , Leonor, Tiago, Licciardi, A, Nava, Claudia L. Lopez, Gallardo, Luis R. Loza, Lungu, Ramona , Luzi, Annalisa, Ma, Wuhua , Μakris, Alexandros , Maheshwarappa, Harish Mallapura , Maraffi, Tommaso , Marcelli, Maria Elena, Mariano, Karim, Marin, Nathalie, Martin, Maëlle, Gonzalez, Mayra Martinez, Matas, Marijana , Matos, Dubier, Maugeri, Jessica Giuseppina , Mazlan, Mohd Zulfakar , Meersch, Melanie , Meher, Ranjan, Mehesry, Tasneem H., Meirik, Maria, Dessap, Armand Mekontso , Mensah, Kwabena , Mercier, Emmanuelle, Midya, Abhirup, Mihaljević, Slobodan , Mirouse, Adrien , Mishra, Prasanna K. , Mistry, Ravi , Moguš, Mate, Nordin, Norbaniza Mohd, Samat, Noryani Mohd, Montini, Luca, Moro, Valeria, Tutillo, Diego Morocho , Mrinal, Sircar, Mudyna, Wojciech, Munta, Kartik, Munusamy, Satheesh , Musso, Stefania, Muttini, Stefano , Irtiza, Ismail Nahla, Nakou, Evi, Narkhede, Amit , Nates, Joseph, Nespoli, M, Nespoli, Francesca, Nikitenko, Artem, Nogueira, Carla, O'Grady, Ross, Odeyemi, Yewande , Ohlsson, Annika , Orsello, Alberto, Palaniswamy, Vijayanand , Palma, Daniela Maria , Palmese, Salvatore , Leal, Jesus N. Pantoja, Papandreou, E., Papanikolaou, Metaxia, Patel, Mayur , Pavlek, Mario , Pedrotti, Niccolò , Hwa, Ngu Pei, Pelagalli, Lorella, Ruiz, Miryam Pérez, Persson, Elin, Petsiou, Athanasia, Philippard, Francois, Piegat, Mariusz, Pili‐Floury, Sébastien, Pinto, Márcia , Piton, Gaël , Plantefève, Gaëtan , Pouplet, Caroline, Pouriki, Sofia, Pradella, Andrea , Prashant, Kumar , Quayle, Alice, Rahmani, Lua S. , Randall, Ian , Ray, Banambar , Reza, Syed T., Ricard, Jean Damien, Riva, Ivano, Rona, Roberto , Rosell, Jon, Rowley, Rebecca, Rumschuessel, Kay, Rundo, Annalisa, Russo, Pierpaolo, Sahu, Samir, Salmon-Gandonnière, Charlotte, Roman, Nandyelly San Juan, Sandefur, Benjamin J. , Santoro, Lida, Sanyal, Rhik, Saravanabavan, Lakshmikanthcharan , Shah, Bhagyesh, Shah, Mehul , Shin, Ming-Hann, Simpson, Shannon, Sinah, Ayush, Singh, D. K., Singh, Nitesh , Singh, Lalit, Skowronski, Lukasz , Sosa, Miguel A. Gama , Spadaro, Savino , Spångfors, Martin , Sperber, Jesper , Spina, Rosario, Srivastava, Anand , Steel, Andrew, Suárez-de-la-Rica, Alejandro , Kumar, Singh Sujeet, Sundrani, Omprakash, Sunil, Nilu, Suparna, Bharadwaj, Surath, Manimala R., Syed, Yadullah, Sztrymf, Benjamin , Tarantino, Stefano, Tileli, Maria, Castro, Hugo Arturo Tirapé , Toledo-Salinas, Otoniel , Tramarin, Jacopo, Tsiftsis, D , Tucić, Iva , León, Jose A. Tutillo, Tutino, Lorenzo, Tyagi, Vijay, Vagdatli, Kyriaki, Varkey, Sneha, Vera, Magdalena , Seth, Magnus Von, Wahlström, C.-G., Ismail, Wan Nasrudin Wan, Winiszewski, Hadrien , Wu, Lun , Zani, Gianluca , Zarka, Jonathan , Zhao, Dawn, Zlotnik, Diane , Bauer, Philippe, Laffey, John G , Labarca, Gonzalo , Alhadi, Abdulmueti , Myatra, Sheila Nainan , Antolini, Laura , Bauer, Philippe R. , Lascarrou, Jean-Baptiste , Szuldrzynski, Konstanty S. , Pelosi, Paolo , Sorbello, Massimiliano , Greif, Robert , Chalkias, Athanasios F. , Pesenti, Antonio, Foti, Giuseppe , Bellani, Giacomo , Investigators, INTUBE Study, Agvald-Öhman, Christina, Ahmad, Meraj, Almekhlafi, Ghaleb A. , Aragão, Irene , Azoulay, Élie , Basto, Marta Lima , Besset, Sebastien, Boni, Elisa, Brazzi, Luca , Broman, Lina, Browne, Alexander, Cappellini, Iacopo , Chao, Anne , Chien, Jung‐Yien , Chou, Nai‐Kuan , Cortegiani, Andrea , Costamagna, Andrea , Cotoia, Antonella , Cracchiolo, Andrea N., Das, Amit, Rosa, Silvia De , Sorbo, Lorenzo Del , Fenza, Raffaele Di , Giacinto, Ida Di , Dudda, Marcel , Ehrentraut, Stefan , Elhadi, Muhammed , Fernandes, Marco, Flores, Fernando, Frat, Jean-Pierre , Fusari, Maurizio , Moraes, Alice Gallo de , Gammaldi, Renato , Gaszynski, Tomasz M , Godet, Thomas , Goffi, Alberto , González-Castro, A. , Guervilly, Christophe , Guitton, Christophe , Huang, Chun‐Kai , Jankowski, Miłosz , Jones, Laura, Karelov, Alexey, Katsoulis, P. , Kaye, Callum T. , Khalidah, Hapiz, Khan, Akram , Ku, Shih‐Chi , Kuo, Lu-Cheng , Lalwani, Jaya, Laserna, Andrés , Lee, Chien‐Chang , Legriel, Stéphane , Li, Yongxing , Licciardi, Anna Lisa, Litton, Edward , Ломиворотов, В. В. , Longhini, Federico , Магомедов, М. А. , Геннадьевна, Марова Надежда , Maseda, Emilio , Mastroianni, Fiore , Michálek, Pavel , Mishra, Prasanna, Mistry, Ravi, Montini, Luca , Montrucchio, Giorgia Giuseppina , Mosier, Jarrod , Mudyna, Wojciech, Müller, Grégoire , Munta, Kartik, Musso, Stefania, Nakou, Evi, Nates, Joseph L. , Nogueira, Carla, Leal, Jesús Nicolás Pantoja, Papandreou, Eleni, Parotto, Matteo , Persson, Elin, Pezzi, Angelo , Philip, Sam, Pinciroli, Riccardo , Pinto, Marcia, Pouplet, Caroline, Regli, Adrian , Roca, Oriol , Rosell, Jon, Ruan, Sheng‐Yuan , Sahu, Samir, Sales, Gabriele , Roman, Nandyelly San Juan, Sánchez‐Hurtado, Luis Alejandro , Santafe, Manel, Sanyal, Rhik, Shah, Bhagyesh, Silva, Monica, Simpson, Shannon, Singh, Atul Kumar , Singh, Lalit, Sosa, Miguel A., Srivastava, Anand, Szakmány, Tamás , Tabah, Alexis , León, José Andrés Tutillo , Wahlstrom, Carl, Hassan, Wan Mohd Nazaruddin Wan , Wang, Kuo‐Chuan , Wu, Jiayan , Yeh, Yu‐Chang , Young, Paul J.

Mayo Clinic

JAMA | March 23, 2021 | Volume: 325 | Issue: 12 | Pages: 1164

10.1001/jama.2021.1727 | PMID 33755076 Get It

Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere, Kerri L. , Riggs, Becky J. , Young, Cameron C. , Newhams, Margaret M. , Maamari, Mia , Walker, Tracie C. , Singh, Aalok R. , Dapul, Heda , Hobbs, Charlotte V. , McLaughlin, Gwenn E., Maddux, Aline B. , Clouser, Katharine N. , Rowan, Courtney M. , McGuire, John K. , Gertz, Shira J. , Muñoz, Álvaro Coronado , Irby, Katherine , Levy, Emily R. , Staat, Mary Allen , Feldstein, Leora R. , Halasa, Natasha , Hall, Mark W. , Kong, Michele , Carroll, Christopher L. , Schuster, Jennifer E. , Doymaz, Sule , Loftis, Laura L. , Tarquinio, Keiko M. , Babbitt, Christopher , Nofziger, Ryan A. , Kleinman, Lawrence C. , Keenaghan, Michael , Spinella, Philip C. , Hume, Janet R. , Wellnitz, Kari , Mack, Elizabeth H. , Flori, Heidi R. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Name, First Name and Middle Initial Last, Gaspers, Mary Glas , Typpo, Katri , Sanders, Ronald C., Schwarz, Adam J. , Harvey, Helen , Mourani, Peter M. , Coates, Bria M. , Bhoojhawon, Guru , Havlin, Kevin , Sullivan, Janice E, Bradford, Tamara T. , Lipton, Susan V., Chen, Sabrina , Kücükak, Suden, Carroll, Ryan W. , Fernandes, Neil D. , Yager, Phoebe H. , Marohn, Kimberly L, Heidemann, Sabrina M. , Cullimore, Melissa L. , Horwitz, Steven M. , Walsh, Rowan, Soma, Vijaya L, Gillen, Jennifer , Zackai, Sheemon, Ackerman, Kate G. , Cholette, Jill M., Hymes, Saul , Overby, Philip , Schwartz, Stephanie P. , Lansell, Amanda , Koncicki, Monica L. , Carcillo, Joseph A. , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Cengiz, Pelin , Levy, Emily R , Young, Cameron C , Randolph, Adrienne G , Spinella, Philip C , Kong, Michele , Hume, Janet R , Hobbs, Charlotte V , Maddux, Aline B , Staat, Mary A , Gertz, Shira J , Schwartz, Stephanie P , Hymes, Saul R , Poussaint, Tina Young , Son, Mary Beth F. , Fitzgerald, Julie C. , Shein, Steven L. , Thomas, Neal J. , Tenforde, Mark W. , Giuliano, John S. , Cvijanovich, Natalie Z , Michelson, Kelly Nicole , Investigators, Overcoming COVID-19, Zinter, Matt S. , Montgomery, Vicki , Sullivan, Janice E, Bembea, Melania M. , Graciano, Ana Lía , Newburger, Jane W. , Marohn, Kimberly L, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Harwayne‐Gidansky, Ilana , Fink, Ericka L. , Kimura, Dai

Mayo Clinic

JAMA Neurology | March 5, 2021 | Volume: 78 | Issue: 5 | Pages: 536

10.1001/jamaneurol.2021.0504 | PMID 33666649 Get It

Preface: promoting research in PLS: current knowledge and future challenges
Mitsumoto, Hiroshi , Conference, all Delegates of the PLS, Ajroud‐Driss, Senda , Andres, Patricia L., Andrews, Jinsy , Babu, Suma , Barohn, Richard J., Benatar, Michael, Chew, Sheena , Conwit, Robin , Davis, Frank, Drory, Vivian E., Elman, Lauren , Fernandes, J. Americo, Ferrey, Dominic, Finegan, Eoin, Fink, John K. , Floeter, Mary Kay, Fournier, Christina , Genge, Angela , Govindarajan, Raghav , Haase, Georg, Hardiman, Orla , Harms, Matthew B. , Hayat, Ghazala , Heiman‐Patterson, Terry , Hill, Bryan Alan, Hübers, Annemarie , Huey, Edward D. , Jawdat, Omar, Kano, Osamu , Kau, Kristen, Kiernan, Matthew C. , Kisanuki, Yasushi, Kurent, Jerome E., Kwan, Justin , Lange, Dale J. , Ludolph, Albert C. , Mackenzie, Ian R. , Manfredi, Giovanni , Marren, David, Family, and, Morita, Mitsuya , Murphy, Jennifer , Nations, Sharon , Oskarsson, Björn , Pellerin, David , Ravits, John , Rezania, Kourosh , Scelsa, Stephen N. , Siddique, Nailah, Simmons, Zachary , Statland, Jeffrey , Blitterswijk, Marka van , Berg, Leonard van den , Walk, David , Warden, Deborah L., Wymer, James , van Blitterswijk, Marka , Simmons, Zachary , Oskarsson, Björn , Hardiman, Orla , Kiernan, Matthew C , Walk, David , Turner, Martin R. , Conference, all Delegates of the PLS, Área-Gómez, Estela , Solano, Juan Marcos , Bede, Peter , Corcia, Philippe , Cudkowicz, Merit , Carvalho, Mamede A. de , Factor‐Litvak, Pam , Granit, Volkan , Family, and, Paganoni, Sabrina , Rouleau, Guy Armand , Siddique, Teepu , Silani, Vincenzo , Traynor, Bryan J.

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | February 20, 2021 | Volume: 21 | Issue: sup1 | Pages: 1-2

10.1080/21678421.2020.1840795 | PMID 33602018 Get It

Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study
Kremyanskaya, Marina , Palmer, Jeanne , McCaul, Kelly, Harrison, Claire , Gerike, Torsten, Pariseau, Joseph, Miranda, Gabriel Salgado Fernandes de, Schwickart, Martin, Giuseppi, Ana Carolina, Zhang, Jennie, Backstrom, Jay T., Gerds, Aaron T. , Vannucchi, Alessandro M. , Passamonti, Francesco , Gotlib, Jason , Ribrag, Vincent , Mead, Adam J. , Mesa, Ruben A. , Kiladjian, Jean‐Jacques , Barosi, Giovanni , Shetty, Jeevan K. , Verstovšek, Srđan

Mayo Clinic

Blood | February 8, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 47-48

10.1182/blood-2020-137265 Get It

Introduction: MF is a clonal stem cell disorder characterized by progressive bone marrow failure, extramedullary hematopoiesis, and debilitating constitutional symptoms. Approximately 60% of pts develop anemia within a year of diagnosis; pts who are transfusion dependent have worse survival and quality-of-life outcomes (Tefferi A, et al. Mayo Clin Proc 2012;87:25-33). Treatment for MF-associated anemia remains critically unaddressed, with no approved therapies available. Luspatercept is a first-in-class erythroid maturation agent that has been shown to increase hemoglobin and reduce transfusion burden in pts with myelodysplastic syndromes (Fenaux P, et al. N Engl J Med 2020;382:140-51) and β-thalassemia (Cappellini MD, et al. N Engl J Med 2020;382:1219-31). Pts have also achieved multiple response episodes with luspatercept (Fenaux P, et al. Blood 2019;134:841). We previously reported findings from the ongoing open-label, phase 2 ACE-536-MF-001 trial evaluating luspatercept in pts with MF-associated anemia (Gerds AT, et al. Blood 2019;134:557). Here we report updated study results, focusing on response in pts requiring RBC transfusions. Methods: 79 pts with MF and anemia were enrolled (Figure). Of these, 43 were requiring RBC transfusions, defined as 6-12 U/84 d prior to treatment, or 4-12 U/84 d for the 3 expansion cohort pts. Pts in Cohort 3B received a stable ruxolitinib (RUX) dose for ≥ 16 wks (40 wks for expansion cohort pts), whereas Cohort 2 pts did not (Figure). Pts in Cohort 3B received a median RUX dose of 20 mg/d (range 5-40) for a median of 73 wks (range 29-359) prior to treatment. Pts received luspatercept every 21 d at a starting dose of 1.0 mg/kg (1.33 mg/kg for 3 expansion cohort pts in Cohort 3B), with doses escalating up to 1.75 mg/kg; 81% and 50% of pts in Cohorts 2 and 3B escalated to 1.75 mg/kg. Primary endpoint for pts receiving transfusions was RBC transfusion-independence (RBC-TI) for ≥ 12 consecutive wks within the first 24 wks on study. However, as responses were observed that did not fall within the 24-wk response window, additional assessments were conducted for the entire treatment duration for RBC-TI and ≥ 50% decrease in RBC transfusions (minimum 4 RBC U decrease) from baseline. Intent-to-treat data were analyzed as of March 29, 2020. Results: Pts in Cohorts 2 and 3B received a median of 8 cycles of luspatercept (range 1-39), for a median (mean) duration of 24 (31) and 23 (39) wks, respectively. Pts in Cohorts 2 and 3B received a median of 2.7 RBC U/28 d (range 1-5) and 2.7 RBC U/28 d (range 2-4), respectively. For the primary endpoint, 2/21 (10%) and 6/22 (27%) pts receiving transfusions in Cohorts 2 and 3B achieved RBC-TI over any consecutive 12 wks during the first 24 wks. Median time to start of first RBC-TI response period in Cohorts 2 and 3B was 1.5 days and 37 days; median duration of response was 49 wks (range 16-82) and 42 wks (range 12-111), respectively. When assessing the entire treatment period, 4/21 (19%) and 8/22 (36%) pts in Cohorts 2 and 3B achieved RBC-TI ≥ 12 wks, respectively. 25% of the RBC-TI responders in both cohorts experienced 2 separate episodes of RBC-TI ≥ 12 wks. Median cumulative duration of all individual ≥ 12-wk response episodes of RBC-TI was 59 wks (range 24-82) in Cohort 2 and 55 wks (range 12-116) in Cohort 3B. 8/21 (38%) and 10/22 (46%) pts in Cohorts 2 and 3B achieved a ≥ 50% reduction in RBC transfusion burden (minimum ≥ 4 U reduction) over 12 wks; of these, 38% and 20% of responders in Cohorts 2 and 3B experienced 2 separate ≥ 12-wk response episodes, and 1 pt (13%) in Cohort 2 experienced 3 separate responses. 4/15 (27%) and 8/14 (57%) pts in Cohorts 2 and 3B who reached 24 wks of treatment achieved clinical benefit and therefore continued luspatercept on an ongoing basis. Safety is reported for all 79 pts on study. 5 (6%) pts had grade 3-4 treatment-related adverse events (AEs); these AEs were diarrhea (n = 2), dehydration (n = 1), and hypertension (n = 3). There were no treatment-related deaths. Treatment-related AEs (any grade) occurring in ≥ 5% of pts were hypertension (13%), bone pain (9%), and diarrhea (5%). 8 (10%) pts had ≥ 1 AE leading to discontinuation. 16 (20%) pts remain on treatment. Conclusions: These longer-term findings suggest durable activity of luspatercept in pts with MF-associated anemia. In addition, a quarter of pts receiving transfusions achieved more than one ≥ 12-wk episode of RBC-TI response with luspatercept. The incidence of grade 3-4 AEs with luspatercept was low. Disclosures Gerds: Roche/Genentech: Research Funding; Celgene: Consultancy, Research Funding; Sierra Oncology: Research Funding; AstraZeneca/MedImmune: Consultancy; Incyte Corporation: Consultancy, Research Funding; Pfizer: Research Funding; Apexx Oncology: Consultancy; CTI Biopharma: Consultancy, Research Funding; Gilead Sciences: Research Funding; Imago Biosciences: Research Funding. Vannucchi:Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Blueprint: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Membership on an entity's Board of Directors or advisory committees. Passamonti:Novartis: Speakers Bureau; BMS: Speakers Bureau; Roche: Other: Support of parent study and funding of editorial support. Kremyanskaya:Constellation Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Bristol Myers Squibb: Research Funding; Protagonist Therapeutics: Consultancy, Research Funding; Astex Pharmaceuticals: Research Funding. Gotlib:CTI Biopharma: Research Funding; Kartos: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Roche: Honoraria, Research Funding; BMS: Research Funding. McCaul:BMS: Speakers Bureau; Seattle Genetics: Speakers Bureau; Karyopharm: Speakers Bureau; Incyte: Speakers Bureau. Ribrag:argenX: Research Funding; pharmamar: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; servier: Consultancy; nanostring: Honoraria, Membership on an entity's Board of Directors or advisory committees; gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; AZD: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other; Infinity: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees; gustave roussy comprehensive cancer center: Current Employment; EPZ: Honoraria, Membership on an entity's Board of Directors or advisory committees; epizyme (EPZ): Research Funding. Mead:Novartis: Consultancy, Honoraria, Other: travel, accommodations, expenses, Research Funding, Speakers Bureau; Celgene/BMS: Consultancy, Honoraria, Other: travel, accommodations, expenses, Research Funding; Abbvie: Consultancy; CTI: Consultancy; Gilead: Consultancy. Harrison:Roche: Honoraria; Gilead Sciences: Honoraria, Speakers Bureau; Incyte Corporation: Speakers Bureau; Janssen: Speakers Bureau; CTI Biopharma Corp: Honoraria, Speakers Bureau; Sierra Oncology: Honoraria; Celgene: Honoraria, Research Funding, Speakers Bureau; Shire: Honoraria, Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau; AOP Orphan Pharmaceuticals: Honoraria; Promedior: Honoraria. Mesa:Sierra Oncology: Consultancy; LaJolla Pharmaceutical Company: Consultancy; Novartis: Consultancy; Incyte: Research Funding; CTI BioPharma: Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Promedior: Research Funding; Bristol Myers Squibb: Research Funding; Samus Therapeutics: Research Funding. Kiladjian:AbbVie: Membership on an entity's Board of Directors or advisory committees; AOP Orphan: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Barosi:Bristol Myers Squibb: Consultancy. Gerike:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Shetty:BMS: Current Employment, Current equity holder in publicly-traded company. Pariseau:Bristol Myers Squibb: Current Employment. Miranda:Bristol Myers Squibb: Current Employment. Schwickart:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Giuseppi:BMS: Current Employment, Current equity holder in publicly-traded company. Zhang:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Backstrom:Acceleron Pharma: Current Employment, Current equity holder in publicly-traded company; BMS: Current equity holder in publicly-traded company. Verstovsek:AstraZeneca: Research Funding; Roche: Research Funding; CTI Biopharma Corp: Research Funding; Genentech: Research Funding; Incyte Corporation: Consultancy, Research Funding; NS Pharma: Research Funding; Novartis: Consultancy, Research Funding; PharmaEssentia: Research Funding; ItalPharma: Research Funding; Sierra Oncology: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Blueprint Medicines Corp: Research Funding; Promedior: Research Funding; Gilead: Research Funding; Protagonist Therapeutics: Research Funding.